Phoenix Clinical Research is pleased to announce that our Good Clinical Practice (GCP) training meets the Minimum Criteria for ICH GCP Training identified by TransCelerate BioPharma as essential to enable mutual recognition of GCP training among trial sponsors. 

Try our GCP training (basics and refreshers) and get your certificate if you are involved in the design, conduct, oversight, or management of a clinical trial. 

Suggested audience: IRB/IEC Members, Clinical Research Organizations (CROs), Sponsors of Clinical Trials, Researchers, Study Coordinators, Key Study Personnel, Principal Investigators, Investigators, Research Nurses, Research Staff, Clinical Operations Managers, Clinical Research Associates (CRAs), Clinical Trial Assistants (CTAs), Medical Writers, etc.

 About TransCelerate: More info are available at: https://transceleratebiopharmainc.com/gcp-training-attestation/training-providers/

 For more info on our GCP training, please visit our website at https://www.phoenix-cr.com/services/trainings-workshops/

 

Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers True Risks For COVID-19?: New Hypothesis

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are great choice drugs for patients with cardiovascular diseases, such as refractory hypertension, coronary artery disease, heart failure, and post-myocardial infarction, besides diabetes and renal insufficiency. Based on experimental animal studies, ACEIs and ARBs increase the number of angiotensin converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. Therefore, this is assumed to happen in human patients chronically using both types of drugs. Beta coronaviruses, to which SARS-Cov-2 belongs to, bind with their anchoring spike S proteins to ACE2 receptors in the lower respiratory tract to gain entry to the lungs. Since patients on chronic use of ACEIs and ARBs might have greater number of ACE2 receptors in their lungs, they will be in greater risk of SARS-CoV-2 infections. The author mentions that this was supported by a Chinese descriptive analysis of 1,099 COVID-19 patients in China, from which patients taking ACEIs and ARBs chronically had severe outcomes. Therefore, he concluded to advise patients on chronic use of ACEIs and ARBs to avoid crowds and mass events to reduce their risk of infection. However, future studies in patients with COVID-19 infections are recommended to confirm chronic therapy with ACEIs or ARBs as a risk factor for severe COVID-19 

Source: Diaz, J., 2020. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. Journal of Travel Medicine, 2020, taaa041, doi:10.1093/jtm/taaa041

Testimonials

  • As an expert in the field with more than 13 years of experience in different functions within the medical department in the international pharmaceutical industry, I can confidently say that I consider Phoenix CR as an integral business partner who understands the need and its' background, get deeply involved in finding creative solutions and all this with the most efficient & professional implementation possible. I simply rely on this company and the related staff members for any medical or clinical project I have with so far an unsurpassed quality in the deliverables and the achievements. Thank you Phoenix CR for being a partner.

    Amal ChalfounClinical, Medical, Regulatory & Quality Manager
    Novo Nordisk
  • I worked several projects with Phoenix CR & I highly recommend them for their professionalism , quality services & punctuality . The great news is that they have expanded their scope of work accross Middle East & Africa.

    Hiba BaroudiSenior Medical Manager Diabetes Levant , Medical Capability Manager Near East
    AstraZeneca
  • One year ago, I received a large research grant for a multi-center investigator-initiated research trial. While that was very exciting for me, I felt a big burden had been laid on my shoulders. How to write a detailed proposal, finalize the budget, get contracts, IRB approval, coordination with other centers, …. At that point, my research team got in touch with Phoenix CR, a well-respected regional CRO. Over the ensuing 12 months, the Phoenix CR team, proved to be of great help. A very reliable group of individuals, well familiar with the whole process, helped me and my team go through all these steps with little difficulty. They put up with hundreds of meetings and emails and phone calls, while maintaining a professional attitude and a very receptive accommodating behavior. I am sure, my journey through that process would have been much harder without this wonderful team. Thank you, Phoenix CR Team for everything.

    Arafat Tfayli, MDDepartment of Internal Medicine Division of Hematology/Oncology
    American University of Beirut Medical Center
  • Phoenix Team consists of highly committed individuals, always ready to go the extra mile to support your business needs with the utmost level of professionalism.

    Maya JarkasMedical Sciences Manager Hematology/Oncology
    AMGEN
  • I would like to thank the Phoenix team for their professionalism, high level of commitment, seeking for perfection and unprecedented support to the event. It was my pleasure to collaborate with them

    Ezzat HamzaMedical Advisor- Respiratory, Inflammation and Autoimmunity Therapy Area
    AstraZeneca
  • Partnering with Phoenix CR would keep the highest level of quality in clinical trials with professionalism

    Mamdouh HassanOperations Manager
    Natural Wellness Egypt